ReviewOncotarget2016
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance.
Mingxiang Ye et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this papercites it
ReviewOncotarget2016
Mingxiang Ye et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.